University of New South Wales (UNSW) researchers are running two new studies on hepatitis C, which could revolutionise treatment for the virus.��w�̃j���[�T�E�X�E�F�[���Y�B�i unsw �j�����҂�����2�‚̐V���Ȍ��������s����C�^�̉��A�E�C���X���ł���revolutionise�̎��Â����܂��B

It is hoped that one study could lead to cure rates of almost 100 percent in those who have just been infected with the virus. 1�‚̂��Ƃ���҂����Ö@�̌����ɂ‚Ȃ��鋰�ꂪ����h�������̂ق�100 ���ł͂�����who���E�C���X�Ɋ������Ă���΂���ł��B The US-funded Australian Trial in Acute Hepatitis C (ATAHC) study involves giving people the drug Pegylated interferon within six months of being diagnosed.�I�[�X�g�����A�̍ٔ��ł̖₢���킹�Řd����}��C�^�̉��i atahc �j�̌����́A�l�X��6�����ȓ��ɖ�̃C���^�[�t�F����pegylated�Ɛf�f����Ă��܂��B

"There is good news and bad news with this virus," said Associate Professor Dore. "�ǂ��j���[�X�ƈ����j���[�X�ɂ́A���̃E�C���X�́A "�y�����ɂ��ƃh�[�A�ł��B "We can cure 50-80 percent of people with current treatments and are working on new ways of administering drugs to improve these rates further, but on the other hand, there is not a lot of awareness about this amongst people with hepatitis C or GPs." "��X�́A���Ö@�̐l�X 50〜80%�Ɏ��g��ł��錻�݂̎��Ö@���̊Ǘ�����コ����V���ȕ�@���A�����̏h�������̂��ڍׂȁA����������ŁA�ӎ����Ȃ��A�����̐l�X�̒��ɂ���C�^�̉��܂��͂�GPS �B "

The problem is that most Hepatitis C patients come to know about their disease when it has advanced.���̖��́A�قƂ�ǂ�C�^�̉����҂��a�C�̂Ƃ��ɗ��邱�Ƃ�m�邽�߂ɂ͍��x�ł��B Dialysis patients are very much at risk for Hepatitis C. So far the accepted treatment has been a dual therapy with Interferon and Ribavarin, earlier the better.���͊��҂͔��ɑ����̃��X�N������܂ł̂Ƃ���A�󂯓��^�̉�c.�f���A���Ö@�Ŏ��Â���ribavarin�C���^�[�t�F�����ƁA�ȑO�̕�D�܂����ł��B

Source����